The United States is broadly recognized as the global leader in drug discovery and innovation, producing more than half of the world’s new molecules in the last decade. Improving patient outcomes through a deeper understanding of disease areas and betterdefned addressable patient populations is revolutionizing drug discovery approaches.By not only developing more effective treatments but also matching the right drug to the right patient, companies are driving a new phase of medical progress.
Arguably the most competitive destinations within the United States in terms of attractiveness, our 2018 research has focused on Massachusetts and California, notably the Boston/Cambridge Area and the San Francisco Bay Area, and also New Jersey as the historic center of pharmaceutical activity. While Massachusetts is lauded for its culture of collaboration, in part attributable to the extreme density of activity, the Bay Area is often cited as the top biotech supercluster due to the sheer volume of activity and high investment fgures, both in terms of NIH funding and venture capital.
Table of Contents
Introducing the U.S. Biopharmaceutical Industry
Fostering an Innovative Ecosystem
Accelerating Pipelines: Drug discovery and development
Manufacturing: Upholding quality
The Spokes of the Wheel: Contract Services
Supply Chain, Distribution and Logistics
Tables and Figures